Objective To evaluate the efficacy and safety of eltrombopag in patients with systemic lupus erythematosus (SLE)-associated immune thrombocytopenia, with a particular focus on thrombotic risk. Methods We conducted a retrospective cohort study of 23 patients with SLE-associated thrombocytopenia treated with eltrombopag. Baseline clinical characteristics, treatment patterns, and outcomes were collected. The primary outcomes were sustained platelet response (≥50 ×10 9 /L at last follow-up) and occurrence of thrombotic events. Exploratory analyses assessed associations between antiphospholipid antibody (aPL) status and thrombosis. Results The mean age was 33.7 ± 12.3 years, and 65.2% were female. aPL positivity was present in 52.2% of patients. A sustained platelet response was achieved in 65.2% of patients, and 21.7% were successfully weaned off corticosteroids. Thrombotic events occurred in 8 patients (34.8%), with arterial events accounting for 50% of cases. The median time to thrombosis was 5.5 months. Thrombosis occurred across a range of platelet counts and was not consistently associated with thrombocytosis. A higher proportion of thrombotic events was observed in aPL-positive patients (41.7% vs 27.3%), although this did not reach statistical significance (OR 1.90, 95% CI 0.33–11.01, p = 0.667). Conclusion Eltrombopag was associated with platelet response in this cohort. Thrombosis was numerically more common in aPL-positive patients, but the small sample and imprecise estimate preclude conclusions about its independent contribution. Without a comparator group, whether these events reflect eltrombopag, the prothrombotic milieu of SLE and aPL antibodies, or their interaction cannot be determined.
Comment on: Exploring the effects of GLP-1 receptor agonists in fibromyalgia: a propensity-matched real-world cohort using the TriNetX research platform: reply
Abstract Objectives We aimed to evaluate the effects of GLP-1 receptor agonists (GLP-1RA) on symptom burden and opioid use in patients with fibromyalgia using real-world data. Methods We conducted a retrospective cohort study using the TriNetX Research Network. Patients with fibromyalgia (≥2 diagnostic encounters) were divided into two groups: those with and without ≥2 prescriptions for GLP-1RA. Propensity score matching at a 1:1 ratio for age, sex and key comorbidities, including diabetes mellitus, obesity, osteoarthritis, inflammatory arthritis, ischemic heart disease, sleep disorders, migraine and medication use, was performed. Outcomes were assessed over a five-year follow-up period. This included opioid use, diagnostic codes for pain, fatigue and disability, body mass index and haemoglobin A1C. Statistical analysis included odds ratios, risk differences and t tests. Results After propensity score matching, there were 48 025 patients in each cohort. Baseline characteristics were well matched, though BMI and Haemoglobin A1c were higher in the GLP-1RA cohort than in non-GLP-1RA users. GLP-1RA use was associated with significantly reduced odds of opioid prescription (OR 0.65), pain diagnostic codes (OR 0.79) and fatigue diagnostic codes (OR 0.68) (all P < 0.001). There was no significant difference in disability-related diagnostic codes. BMI and HbA1C remained higher in patients on GLP-1RA. Conclusion GLP-1RA use was associated with reduced opioid prescription and a reduction in the use of ICD-10 codes related to fibromyalgia, potentially reflecting lower symptom burden. Further studies using validated outcome measures are needed to confirm these findings.
The Effectiveness of Sacubitril/Valsartan in Systemic Sclerosis Patients with Heart Failure: A Retrospective Analysis
Introduction: Cardiac involvement in patients with systemic sclerosis (SSc) can present variably from being asymptomatic to manifesting with heart failure, conduction abnormalities, pulmonary hypertension, and pericardial effusion. Symptomatic cardiac involvement portends a poor prognosis and worse overall survival. Sacubitril/valsartan (SV), an angiotensin receptor neprilysin inhibitor, has been shown to significantly reduce hospitalization rates and morbidity in patients with heart failure with reduced ejection fraction (HFrEF). This study aimed to investigate the effects of SV treatment in patients with SSc and heart failure. Methods: A retrospective analysis of patients with SSc was conducted using an electronic data capture tool. Patients with SSc treated with SV between January 2015 and August 2023 were identified. Comprehensive clinical phenotyping and longitudinal data analysis were performed to characterize the sub-type of patients and evaluate clinical outcomes, including hospitalizations and mortality, laboratory markers, and echocardiographic findings. Results: Twenty-four patients with SSc were treated with SV for a mean duration of 20.6 months. HFrEF was the primary indication for SV use in 91% of patients, primarily due to non-ischemic cardiomyopathy (87.5%). There was a significant reduction in systolic blood pressure from 128 mmHg to 114 mmHg (p < 0.001) and NT-proBNP levels from 15,130 pg/mL to 5082 pg/mL (p = 0.046). In the 19 patients with baseline and follow-up echocardiograms, there was a significant improvement in LVEF from 40.3% to 47.7% (p = 0.014). Hypotension was a common side effect leading to discontinuation of SV (n = 4, 16.7%). Serum creatinine had trends of improvement (1.9 mg/dL to 1.3 mg/d), though it did not reach statistical significance (p = 0.057). Conclusions: This study showed that SV effectively improved cardiac symptoms and function in patients with SSc presenting with HFrEF. Further prospective studies are needed to confirm these findings and explore the role of SV in the treatment of other manifestations of SSc.
A Rare Cause of Severe Hypoglycemia in Intracranial Hemangiopericytoma Associated With Non-Islet Cell Tumor Hypoglycemia